Inclusion Criteria for All the Participants:  Ability to provide a written informed consent 40-75 years old  Exclusion Criteria for All the Participants:  Inability to comply with study procedures Pregnancy or lactating women Recipients of organ transplant or prior non-autologous (allogeneic) bone marrow transplant or stem cell transplant Recipients of blood transfusion within 7 days prior to study blood draw Recipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancer  Inclusion Criteria for Cancer Arm Participants:  Confirmed diagnosis or suspicious cases of one of the 22 types of malignancies within 42 days prior to study blood draw No prior or ongoing anti-cancer therapy (local or systematic) prior to study blood draw  Exclusion Criteria for Cancer Arm Participants:  Known prior diagnosis of malignancies Other current malignant diseases or multiple primary tumors No confirmed diagnosis of cancer by histopathological or radiological assessments within 42 days of study blood draw, or diagnosis of a benign disease by histopathological assessments, or inability to characterize whether the lesion is malignant or benign Non-small-cell lung cancer patients with ground-class nodularity by radiological examination  Inclusion Criteria for Benign Diseases Arm Participants:  Confirmed diagnosis of benign diseases corresponding to the tumor types in the Cancer Arm by histopathological or radiological assessments within 90 days prior to study blood draw No prior treatment of benign diseases prior to study blood draw  Exclusion Criteria for Benign Diseases Arm Participants:  History of malignancies Current malignancies or precancerous lesions No confirmed diagnosis of a benign disease by radiological, endoscopic or histopathological assessments within 42 days of study blood draw, or inability to characterize whether the lesion is malignant or benign  Inclusion Criteria for Non-tumor (Healthy) Arm Participants:  No cancer-related symptoms or discomfort within 30 days prior to study blood draw No clinically significant finding by LDCT or ultrasound No clinically significant finding by breast ultrasound or Molybdenum Target Mammography Detection, or Thinprep cytologic test (TCT) detection for female participants No active hepatitis B or hepatitis C infection  Exclusion Criteria for Non-tumor (Healthy) Arm Participants:  Prior or ongoing treatment of cancer within 3 years prior to study blood draw Clinically significant or uncontrolled comorbidities